Cargando…

HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL

INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in...

Descripción completa

Detalles Bibliográficos
Autores principales: TORTATO, SIMONE, POCHINI, ALBERTO DE CASTRO, ANDREOLI, CARLOS VICENTE, COHEN, CARINA, LARA, PAULO HENRIQUE SCHMIDT, BELANGERO, PAULO SANTORO, EJNISMAN, BENNO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ATHA EDITORA 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979357/
https://www.ncbi.nlm.nih.gov/pubmed/35431635
http://dx.doi.org/10.1590/1413-785220223001e244410
_version_ 1784681158827573248
author TORTATO, SIMONE
POCHINI, ALBERTO DE CASTRO
ANDREOLI, CARLOS VICENTE
COHEN, CARINA
LARA, PAULO HENRIQUE SCHMIDT
BELANGERO, PAULO SANTORO
EJNISMAN, BENNO
author_facet TORTATO, SIMONE
POCHINI, ALBERTO DE CASTRO
ANDREOLI, CARLOS VICENTE
COHEN, CARINA
LARA, PAULO HENRIQUE SCHMIDT
BELANGERO, PAULO SANTORO
EJNISMAN, BENNO
author_sort TORTATO, SIMONE
collection PubMed
description INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in the HA group a single dose of intra-articular hylan G-F 20 was administered and in the T control group a dose of triamcinolone 20 mg was administered. The participants were evaluated at 1 week, 1, 3, and 6 months after the procedure. The patients were evaluated for pain, range of motion, Constant score, modified UCLA score, and SPADI. RESULTS: Seventy patients met the inclusion criteria and were randomized to the HA (38) and T (32) groups. Improvements in range of motion were significant (p > 0.05). We observed decreases in the general visual analog scale (VAS) for pain in both groups, especially in the cases of mild and moderate arthritis that received hyaluronic acid (mean values from 8.1 initially to 4.9 after 6 months) (p = 0). CONCLUSIONS: Both injections led to a decrease in pain and an increase in patient satisfaction. The results tend to be better and longer lasting in patients receiving hyaluronic acid. Level of evidence II b; Cohort study.
format Online
Article
Text
id pubmed-8979357
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher ATHA EDITORA
record_format MEDLINE/PubMed
spelling pubmed-89793572022-04-15 HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL TORTATO, SIMONE POCHINI, ALBERTO DE CASTRO ANDREOLI, CARLOS VICENTE COHEN, CARINA LARA, PAULO HENRIQUE SCHMIDT BELANGERO, PAULO SANTORO EJNISMAN, BENNO Acta Ortop Bras Original Article INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in the HA group a single dose of intra-articular hylan G-F 20 was administered and in the T control group a dose of triamcinolone 20 mg was administered. The participants were evaluated at 1 week, 1, 3, and 6 months after the procedure. The patients were evaluated for pain, range of motion, Constant score, modified UCLA score, and SPADI. RESULTS: Seventy patients met the inclusion criteria and were randomized to the HA (38) and T (32) groups. Improvements in range of motion were significant (p > 0.05). We observed decreases in the general visual analog scale (VAS) for pain in both groups, especially in the cases of mild and moderate arthritis that received hyaluronic acid (mean values from 8.1 initially to 4.9 after 6 months) (p = 0). CONCLUSIONS: Both injections led to a decrease in pain and an increase in patient satisfaction. The results tend to be better and longer lasting in patients receiving hyaluronic acid. Level of evidence II b; Cohort study. ATHA EDITORA 2022-01-28 /pmc/articles/PMC8979357/ /pubmed/35431635 http://dx.doi.org/10.1590/1413-785220223001e244410 Text en https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
TORTATO, SIMONE
POCHINI, ALBERTO DE CASTRO
ANDREOLI, CARLOS VICENTE
COHEN, CARINA
LARA, PAULO HENRIQUE SCHMIDT
BELANGERO, PAULO SANTORO
EJNISMAN, BENNO
HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title_full HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title_fullStr HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title_full_unstemmed HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title_short HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
title_sort hylan g-f 20 versus triamcinolone in the treatment of primary shoulder osteoarthritis. randomized trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979357/
https://www.ncbi.nlm.nih.gov/pubmed/35431635
http://dx.doi.org/10.1590/1413-785220223001e244410
work_keys_str_mv AT tortatosimone hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT pochinialbertodecastro hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT andreolicarlosvicente hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT cohencarina hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT larapaulohenriqueschmidt hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT belangeropaulosantoro hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial
AT ejnismanbenno hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial